ReviewToxins2018
Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Targeting Uremic Toxins in Chronic Kidney Disease: Current Challenges and Emerging Therapeutic Strategies.Toxins · 2026Review
- Review
- Benchmarking the urinary transplant metabolome of kidney transplant recipients using healthy organ donors.Frontiers in transplantation · 2026Article
- Clinical Pharmacokinetic-Pharmacodynamic Relationships of Pharmacological Strategies for Attenuating p-Cresyl Sulfate in Patients with Kidney Disease.Clinical pharmacokinetics · 2025Article
- SGLT2 Inhibitors Confer Cardiovascular Protection via the Gut-Kidney-Heart Axis: Mechanisms and Translational Perspectives.Journal of cardiovascular development and disease · 2025Review
- Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis.Cellular and molecular life sciences : CMLS · 2024Review
- Hemodiafiltration with endogenous reinfusion for uremic toxin removal in patients undergoing maintenance hemodialysis: a pilot study.Renal failure · 2024Article
- Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis.Physiological reviews · 2023Review
- Role of Gut Microbiota, Immune Imbalance, and Allostatic Load in the Occurrence and Development of Diabetic Kidney Disease.Journal of diabetes research · 2023Review
- Microbiome in Chronic Kidney Disease.Life (Basel, Switzerland) · 2022Review
- Decreased Cathepsin-K Mirrors the Severity of Subclinical Atherosclerosis in Kidney Transplant Recipients.Reviews in cardiovascular medicine · 2022Article
- Indoxyl sulfate impairsExperimental biology and medicine (Maywood, N.J.) · 2022Article
- mbDenoise: microbiome data denoising using zero-inflated probabilistic principal components analysis.Genome biology · 2022Article
- The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease.Clinical kidney journal · 2022Article
- Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021Review
- Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease.Nature reviews. Nephrology · 2021Review
- Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function.Clinical kidney journal · 2021Article
- Review
- Gut dysbiosis and mortality in hemodialysis patients.NPJ biofilms and microbiomes · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-transplanted and transplanted patients with chronic kidney disease (CKD) differ in terms of mortality and the risk of clinical events. This difference is probably due to the difference of both traditional and non-traditional risk factors. Uremic retention solutes may constitute important non-traditional risk factors in this population. In the present review, we selected a set of uremic toxins that have been associated with harmful effects, and are an appealing target for adjuvant therapy in CKD. For each toxin reviewed here, relevant studies were selected and the relationship with hard clinical outcomes of uremic toxins were compared between non-transplanted CKD patients and transplanted patients taking into account the level of glomerular filtration rate in these two situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.